Tigecycline's Core Structure
Tigecycline is a glycylcycline antibiotic, derived from minocycline with key modifications: a tert-butylglycylamido group at position C9 and a 6-D-methyl modification on the sugar ring.[1] These changes expand its binding to the bacterial 30S ribosomal subunit, unlike earlier tetracyclines.
How Structure Enables Activity Against Resistant Bacteria
Tigecycline's bulky C9 side chain sterically hinders ribosomal protection proteins (RPPs, like Tet(O)) and efflux pumps (like Tet(A)) that eject or shield the ribosome from tetracyclines.[1][2] Standard tetracyclines fit these mechanisms, but tigecycline's size blocks access, restoring binding to the A-site of the 16S rRNA. It achieves 4-8x tighter binding (Kd ~10-50 nM vs. 100-500 nM for tetracycline).[3]
Specific Resistance Bypass Mechanisms
- Efflux Resistance: The C9 glycylamido group increases hydrophilicity and size, reducing pump recognition. Gram-negative pumps like AcrAB-TolC expel tetracyclines but transport tigecycline less efficiently.[2]
- Ribosomal Protection: RPPs use GTPase activity to dislodge tetracyclines; tigecycline's extended scaffold resists displacement.[1]
- Target Mutation Tolerance: Minor 16S rRNA mutations (e.g., G1058C) weaken tetracycline binding more than tigecycline's.[3]
This makes tigecycline active against MRSA, VRE, and multidrug-resistant Enterobacteriaceae, though emerging Tet(X) enzymes oxidize its D-ring, conferring resistance.[4]
Limitations and Emerging Resistance
Tigecycline lacks activity against Pseudomonas and Proteus due to poor uptake, not structure-related resistance.[1] New plasmid-mediated Tet(X3-X6) variants metabolize it, bypassing structural protections.[4]
Comparison to Tetracyclines
| Feature | Tetracycline | Tigecycline |
|---------|-------------|-------------|
| C9 substituent | H | Tert-butylglycylamido |
| Efflux susceptibility | High (Tet(A/B)) | Low |
| RPP susceptibility | High (Tet(M/O)) | Low |
| MIC vs. resistant E. coli | >32 µg/mL | 0.5-2 µg/mL[2] |
Sources
[1] PubMed: Glycylcycline structure-activity
[2] Nature Reviews Microbiology: Tigecycline mechanisms
[3] Antimicrobial Agents Chemotherapy: Binding studies
[4] mBio: Tet(X) tigecycline resistance